Fig 1: Protein-protein interaction network on ANXA4, NF-?B p50 and TP53 was constructed using Cbioportal database. Each node represents a protein, while the edges between the nodes represent the interaction between the proteins. The thickness of the line correlates to the strength of the association. The stronger the interaction between proteins, the more connectivity, the bigger the nodes and the darker the color.
Fig 2: Nuclear expression of ANXA4 and NF-?B p50 in different ovarian tissues. Immunohistochemistry was performed to detect ANXA4 and NF-?B p50 expression in normal ovarian tissues and tissues from different subtypes of ovarian cancer (magnification ×400). OCCC, ovarian clear cell carcinoma; ANXA4, Annexin IV; NF-?B, nuclear factor-?-light-chain-enhancer of activated B cells.
Fig 3: Expression levels of ANXA4, NF-?B p50 and mutant p53 in ovarian clear cell carcinoma tissues (magnification ×400). ANXA4, Annexin IV; NF-?B, nuclear factor-?-light-chain-enhancer of activated B cells.
Fig 4: The association between ANXA4 and NF-?B p50 expression on the survival time of patients with ovarian clear cell carcinoma. Kaplan-Meier survival analysis demonstrated that high expression levels of ANXA4 and NF-?B p50 were independent risk factors for overall survival. ANXA4, Annexin IV; NF-?B, nuclear factor-?-light-chain-enhancer of activated B cells.
Fig 5: Interaction between ANXA4 and NF-?B p50 in OCCC cell lines. (A) Co-immunoprecipitation analysis was performed to determine the association between ANXA4 and NF-?B p50. (B) Double-labeling immunofluorescence analysis demonstrated co-localization of ANXA4 and NF-?B p50 in OCCC cells. (C) Western blot analysis was performed to detect ANXA4 and NF-?B p50 expression following transfection of the ANXA4 gene. (D) Immunocytochemistry analysis was performed to detect ANXA4 and NF-?B p50 expression following transfection of the ANXA4 gene. *P<0.05. ANXA4, Annexin IV; NF-?B, nuclear factor-?-light-chain-enhancer of activated B cells; OCCC, ovarian clear cell carcinoma; IB, immunoblotting; IP, immunoprecipitation; NOT, anti-IgG antibody (negative control).
Supplier Page from Abcam for Anti-NFkB p105 / p50 antibody